Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Cancer Rep (Hoboken) ; 5(9): e1648, 2022 09.
Article in English | MEDLINE | ID: mdl-35668046

ABSTRACT

BACKGROUND: Pancreatic acinar cell carcinoma is rare; it accounts for 1% of all malignant pancreatic exocrine tumors. Although surgical resection is an option for curative treatment, the safety and efficacy of conversion surgery in patients with pancreatic acinar cell carcinoma with metastasis remain unknown. CASE: A 67-year-old man with epigastric pain and a pancreatic tumor was referred to our hospital. Computed tomography revealed a large tumor with a maximum diameter of 67 mm at the pancreatic head and a 23-mm mass in the left upper abdominal cavity. Because a definitive diagnosis could not be made based on endoscopic ultrasonography-guided fine needle aspiration biopsy findings, a diagnostic laparoscopy was performed. The tumor in the greater omentum at the left upper abdomen, resected under laparoscopy, was histopathologically diagnosed as pancreatic acinar cell carcinoma. Therefore, the pancreatic tumor was diagnosed as an unresectable pancreatic acinar cell carcinoma with a solitary peritoneal dissemination. The size of the main pancreatic tumor decreased to 15 mm after 18 courses of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin). Subsequently, the patient underwent conversion surgery, and the initial diagnosis of pancreatic acinar cell carcinoma was confirmed on pathological examination. The patient was discharged 31 days postoperatively, following which he received adjuvant chemotherapy with S-1. No sign of recurrence has been observed for 32 months after surgical resection. CONCLUSION: FOLFIRINOX may be effective in patients with pancreatic acinar cell carcinoma, and conversion surgery after FOLFIRINOX may be applicable to selective patients.


Subject(s)
Carcinoma, Acinar Cell , Pancreatic Neoplasms , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Acinar Cell/diagnosis , Carcinoma, Acinar Cell/drug therapy , Carcinoma, Acinar Cell/surgery , Fluorouracil , Humans , Irinotecan/therapeutic use , Leucovorin , Male , Oxaliplatin/therapeutic use , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/surgery , Pancreatic Neoplasms
2.
Oncology ; 99(4): 225-233, 2021.
Article in English | MEDLINE | ID: mdl-33601391

ABSTRACT

BACKGROUND: This study aimed to investigate the efficacy of enteral supplementation of vitamin B12 for vitamin B12 deficiency in patients who underwent total gastrectomy for gastric cancer. METHODS: The study enrolled 133 patients who underwent total gastrectomy for gastric cancer at Kochi Medical School. Clinical data were obtained to investigate associations between vitamin B12 supplementation and vitamin B12 levels. Vitamin B12 deficiency was defined as serum vitamin B12 less than 200 pg/mL. Baseline characteristics and changes in hematological variables, including vitamin B12 levels, were examined. RESULTS: Vitamin B12 deficiency was present in 71.4% of the 133 patients. Vitamin B12 levels at 3, 6, and 12 months after enteral supplementation were 306 pg/mL, 294 pg/mL, and 367 pg/mL, respectively, which were all significantly higher than those before supplementation (p < 0.001 for all comparisons). The median red blood cell count at 3, 6, and 12 months after enteral supplementation were 380 × 104/mm3, 394 × 104/mm3, and 395 × 104/mm3, respectively, which were all significantly higher than those before supplementation (p = 0.020, p = 0.001, and p = 0.003, respectively). Vitamin B12 levels at 3, 6, and 12 months after supplementation were significantly higher in patients supplemented enterally than those supplemented parenterally (p < 0.001 for all comparisons). CONCLUSIONS: Vitamin B12 deficiency was found in 71.4% of postoperative patients who underwent total gastrectomy for gastric cancer, and enteral vitamin B12 supplements might be effective to improve anemia in these patients.


Subject(s)
Anemia/etiology , Anemia/therapy , Enteral Nutrition/methods , Gastrectomy/adverse effects , Vitamin B 12 Deficiency/etiology , Vitamin B 12 Deficiency/therapy , Vitamin B 12/administration & dosage , Adult , Aged , Aged, 80 and over , Anemia/blood , Dietary Supplements , Female , Humans , Male , Middle Aged , Postoperative Period , Retrospective Studies , Stomach Neoplasms/surgery , Treatment Outcome , Vitamin B 12/blood , Vitamin B 12 Deficiency/blood
3.
Surg Today ; 50(11): 1486-1495, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32542414

ABSTRACT

PURPOSE: To investigate the usefulness of clinicopathological systemic inflammatory response and nutritional biomarkers for predicting the efficacy of nivolumab in patients with advanced gastric cancer. METHODS: The subjects of this study were 29 patients who received nivolumab treatment for advanced gastric cancer at the Kochi Medical School between 2017 and 2019. Clinicopathological information, including systemic inflammatory response data, were obtained to investigate the associations between baseline cancer-related prognostic variables and survival outcomes. RESULTS: Immune-related adverse events (irAEs) of any grade were identified in 34.5% (10/29) of the patients. The median progression-free survival of patients with irAEs was significantly greater than that of patients without irAEs (5.8 months vs. 1.2 months, respectively; P = 0.028). The neutrophil to lymphocyte ratio (NLR) after 4 weeks of treatment in the complete response (CR) or partial response (PR) group was significantly lower than that in the stable disease (SD) or progression disease (PD) group (2.2 vs. 2.9, respectively; P = 0.044). The prognostic nutrition index (PNI) before treatment in the CR or PR group was significantly higher than that in the SD or PD group (37.1 vs. 32.1, respectively; P = 0.011). The PNI 8 weeks after treatment and the Glasgow prognostic score (GPS) before treatment were significantly associated with a poor outcome. CONCLUSION: The irAE, NLR, PNI, and GPS may be useful predictive markers for nivolumab efficacy in patients with advanced gastric cancer.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Nivolumab/therapeutic use , Nutrition Assessment , Stomach Neoplasms/drug therapy , Systemic Inflammatory Response Syndrome/chemically induced , Aged , Aged, 80 and over , Antineoplastic Agents, Immunological/adverse effects , Female , Humans , Leukocyte Count , Lymphocytes/immunology , Male , Middle Aged , Neutrophils/immunology , Nivolumab/adverse effects , Predictive Value of Tests , Severity of Illness Index , Stomach Neoplasms/immunology , Treatment Outcome
4.
Data Brief ; 22: 359-364, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30596132

ABSTRACT

This data article contains the data on metabolic profiling of healthy human subjects' plasma before and after administration of the Japanese Kampo medicine maoto. Four healthy human subjects were recruited. Plasma samples were collected before and 0.25, 0.5, 1, 2, 4 and 8 h after maoto treatment. Endogenous and exogenous compounds in plasma were analyzed using MS. Endogenous compounds including saccharides, amino acids, organic acids and other hydrophilic metabolites were semi-quantitatively measured using GC-MS/MS. Lipid mediators such as arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid were semi-quantitatively measured using LC-MS/MS. Maoto constituents in plasma were quantitatively measured using LC-MS/MS. The data files contain the area ratio values, which were normalized to the intensity of the internal standard, and plasma concentration of maoto compounds. The data article is related to the research article titled "Phenotyping analysis of the Japanese Kampo medicine maoto in healthy human subjects using wide-targeted plasma metabolomics" (Kitagawa et al., 2018).

5.
J Pharm Biomed Anal ; 164: 119-127, 2019 Feb 05.
Article in English | MEDLINE | ID: mdl-30368117

ABSTRACT

Traditional herbal medicine (THM) consists of a vast number of compounds that exert pharmacological effects throughout the body. Comprehensive phenotyping analysis using omics is essential for understanding the nature of THM in detail. We previously reported that the Japanese Kampo medicine maoto ameliorated flu-like symptoms in a rat infection model and dynamically changed plasma metabolites as indicated by metabolome analysis. The aim of this study was to apply wide-targeted plasma metabolomics with quantitative analysis of maoto compounds in a human clinical trial to evaluate the effect of maoto on plasma metabolites. Four healthy human subjects were recruited. Plasma samples were collected before and 0.25, 0.5, 1, 2, 4 and 8 h after maoto treatment. Wide-targeted metabolomics and quantitative analysis of the main chemical constituents of maoto were then performed. Plasma metabolome analysis revealed that maoto administration decreased essential amino acids including branched-chain amino acids (BCAAs) and increased various kinds of ω-3 fatty acids including eicosapentaenoic acid and docosahexaenoic acid, consistent with previous studies in rats. Fifteen of the major compounds in maoto were identified in the systemic circulation. Finally, the correlation between endogenous metabolites and maoto compounds in plasma was analyzed and the results indicated that the decrease in plasma BCAAs might be caused by ephedrines present in maoto. The present study demonstrated that plasma metabolomic studies of endogenous and exogenous metabolites are useful for elucidating the mechanism of action of THM.


Subject(s)
Amino Acids, Branched-Chain/metabolism , Drugs, Chinese Herbal/pharmacology , Fatty Acids, Omega-3/metabolism , Medicine, Kampo/methods , Metabolomics/methods , Adult , Amino Acids, Branched-Chain/blood , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/metabolism , Fatty Acids, Omega-3/blood , Healthy Volunteers , Humans , Male , Metabolome , Metabolomics/instrumentation
6.
Anticancer Res ; 34(12): 7297-301, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25503163

ABSTRACT

UNLABELLED: The present study evaluated the efficacy of lafutidine, a histamine H2 receptor antagonist, for reducing gastrointestinal toxicities during adjuvant chemotherapy using oral fluorouracil anticancer drugs for gastric cancer. PATIENTS AND METHODS: Patients with stage II (T1 cases excluded) or stage III gastric adenocarcinoma who underwent gastrectomy with D2 lymphadenectomy achieving R0 resection from 2011 to 2013 were prospectively enrolled in the study. Patients were randomly assigned to either S-1 treatment or S-1 plus lafutidine treatment. Quality of life and gastrointestinal toxicity were evaluated before chemotherapy and at 2, 4, and 6 weeks after the beginning of treatment. RESULTS: The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs. 83%, respectively; p=0.002). The grades of diarrhea and nausea during chemotherapy were also significantly lower compared to those before chemotherapy in patients receiving S-1 plus lafutidine than in those administered S-1 alone. The rate of patients requiring a dose reduction or interruption of S-1 was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (30% vs. 83%, respectively; p=0.027). CONCLUSION: Lafutidine might be useful not only for preventing gastrointestinal toxicities during adjuvant chemotherapy for gastric cancer, but also for improving compliance with taking oral fluorouracil anticancer drugs. However, this indication needs to be confirmed in a larger, prospective, randomized, controlled trial.


Subject(s)
Acetamides/therapeutic use , Diarrhea/prevention & control , Fluorouracil/adverse effects , Histamine H2 Antagonists/therapeutic use , Nausea/prevention & control , Piperidines/therapeutic use , Pyridines/therapeutic use , Stomach Neoplasms/drug therapy , Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/adverse effects , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant/adverse effects , Diarrhea/chemically induced , Diarrhea/drug therapy , Drug Combinations , Female , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Gastrectomy , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/pathology , Humans , Lymph Node Excision , Male , Middle Aged , Nausea/chemically induced , Nausea/drug therapy , Oxonic Acid/adverse effects , Oxonic Acid/therapeutic use , Prospective Studies , Quality of Life , Stomach Neoplasms/surgery , Tegafur/adverse effects , Tegafur/therapeutic use
7.
J Gastroenterol Hepatol ; 29(4): 870-7, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24224518

ABSTRACT

BACKGROUND AND AIMS: In recent years, bone marrow (BM)-derived stem cell repopulation of injured organs has been increasingly observed; however, the extent to which it occurs and its clinical relevance remain unclear. Here, we investigated on the potential of extrahepatic stem cells to become hepatocytes using the treatment of the oral supplementation of branched-chain amino acids (BCAA). METHODS: In the first, Sprague-Dawley (SD) rats were administered BCAA to promote liver regeneration; in the second, syngenic liver transplantations using wild-type SD rats that do not express green fluorescent protein (GFP) as syngenic donors and GFP-transgenic SD rats as recipients to confirm that an extrahepatic source of cells (GFP(+)) could repopulate the transplanted (GFP(-)) liver were performed. RESULTS: Treatment of the oral supplementation of BCAA for 2-3 weeks before transplantation to promote liver regeneration resulted in greater than 7 days graft volume, with extensive spotty conversion of a small wild-type graft to the recipient GFP(+) genotype. The treatment by oral supplementation of BCAA resulted in higher levels of CD34+SDF+c-kit+ stem cells in the blood and liver after liver transplantation. Liver repopulation could be achieved with hepatocytes that bone marrow-derived from stem cells proliferated. CONCLUSIONS: We have identified extrahepatic stem cell migration from the BM to the injured liver as a mechanism underlying liver regeneration that supports hepatocyte proliferation in diseased liver. Our results suggested that BCAA is able to mobilize a population of BM-derived cells that contribute to hepatic regeneration.


Subject(s)
Amino Acids, Branched-Chain/pharmacology , Bone Marrow Cells/cytology , Cell Differentiation/drug effects , Hepatocytes , Liver Regeneration , Liver/cytology , Liver/physiology , Stem Cell Transplantation , Stem Cells/cytology , Stem Cells/drug effects , Administration, Oral , Amino Acids, Branched-Chain/administration & dosage , Animals , Cell Proliferation/drug effects , Cells, Cultured , Liver Regeneration/drug effects , Models, Animal , Rats , Rats, Sprague-Dawley , Stimulation, Chemical , Time Factors
8.
Surg Today ; 43(7): 720-6, 2013 Jul.
Article in English | MEDLINE | ID: mdl-22890582

ABSTRACT

PURPOSES: The long-term outcomes of branched-chain amino acids (BCAA) administration after hepatic resection in patients with hepatocellular carcinoma (HCC) remain unclear. This study assessed the effect of oral supplementation with BCAA on the development of liver tumorigenesis after hepatic resection in HCC patients. METHODS: Fifty-six patients were randomly assigned to receive either BCAA supplementation (Livact group, n = 26) or a conventional diet (Control group, n = 30). Twenty-six patients in the BCAA group were treated orally for 2 weeks before and 6 months after hepatic resection. Postoperative tumor recurrence was continuously evaluated in all patients by measuring various clinical parameters. RESULTS: There was no significant difference in the overall survival rate between the two patient groups; however, the recurrence rate at 30 months after surgery was significantly better in the Livact group in comparison to the Control group. Interestingly, the tumor markers, such as AFP and PIVKA-II, significantly decreased at 36 months after liver resection in the Livact group in comparison to the Control group. CONCLUSIONS: Oral supplementation of BCAA reduces early recurrence after hepatic resection in patients with HCC. This treatment regimen offers potential benefits for clinical use in such patients, even in cases with a well-preserved preoperative liver function.


Subject(s)
Amino Acids, Branched-Chain/administration & dosage , Carcinoma, Hepatocellular/surgery , Dietary Supplements , Hepatectomy , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/prevention & control , Administration, Oral , Aged , Female , Humans , Male , Middle Aged , Postoperative Care , Prospective Studies , Treatment Outcome
9.
Mol Biol Rep ; 39(12): 10803-10, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23053977

ABSTRACT

Oxidative stress (OS) plays an important role in the progression of chronic liver disease including organ injury and hypoalbuminemia. Long-term oral supplementation with branched-chain amino acids (BCAAs) can inhibit liver dysfunction but their role in the prevention of liver fibrosis and injury to the liver is unclear. The aim of this study was to assess how BCAAs preserve liver function from OS. To investigate how BCAAs specifically prevent OS, we evaluated the effect of oral supplementation with BCAAs on OS using a rat liver cirrhosis model. Liver cirrhosis was induced in ten male Sprague-Dawley rats by administering carbon tetrachloride for 12 weeks. Five of the ten carbon tetrachloride-treated rats were assigned to a control group and five to a BCAA group. BCAA-supplementation significantly preserved plasma albumin concentrations and significantly inhibited the occurrence of organ injury as determined by blood chemistry analysis. Hepatic expression of OGG1 mRNA was increased in the BCAA group compared to the control group. In the BCAA group, increased hepatic levels of OGG1 protein were found by western blot. On the other hand, the number of 8-OHdG-positive cells was significantly higher in liver sections taken 1 month after carbon tetrachloride treatment. Furthermore, OGG1-positive cells were significantly increased in the hepatocytes around the central vein. BCAA was found to reduce OS, which could possibly lead to a decrease in the occurrence of hypoalbuminemia and organ injury. Our results indicate that BCAA-enriched nutrients stimulate antioxidant DNA repair in a rat model of liver injury induced by carbon tetrachloride.


Subject(s)
Amino Acids, Branched-Chain/pharmacology , Amino Acids, Branched-Chain/therapeutic use , Antioxidants/pharmacology , DNA Repair/drug effects , Dietary Supplements , Liver Diseases/drug therapy , Liver Diseases/pathology , 8-Hydroxy-2'-Deoxyguanosine , Animals , Biomarkers/metabolism , Blotting, Western , Carbon Tetrachloride , Cytokines/metabolism , DNA Glycosylases/metabolism , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/metabolism , Disease Models, Animal , Food , Immunohistochemistry , Liver/drug effects , Liver/enzymology , Liver/pathology , Liver Diseases/blood , Male , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley
10.
World J Gastrointest Surg ; 4(5): 131-4, 2012 May 27.
Article in English | MEDLINE | ID: mdl-22655128

ABSTRACT

We report a case of adult intussusception caused by cecal adenocarcinoma that was treated by laparoscopy-assisted ileocecal resection following reduction by contrast enema and preoperative colonoscopy. A 68-year-old male with cecal cancer was admitted to our hospital because of colicky abdominal pain after taking a laxative. His abdomen was distended, and a mass was palpable in the right upper quadrant, which appeared as a target- or sausage-shaped lesion by ultrasonograhpy and computed tomography. A contrast enema using water-soluble material showed a cup-shaped filling defect characterized by intussusception in the ascending colon. This round defect with a clear margin was pushed gradually back into the cecum by the enema pressure. Re-occurrence of the intussusception is easily released by colonoscopy. We performed laparoscopy-assisted ileocecal resection of a protruding tumor measuring 6.5 cm × 5.0 cm × 3.5 cm from the cecum, with D3 lymph node dissection. Histological examination revealed a well-differentiated adenocarcinoma that had invaded the serosa without permeating the lymphatic or venous capillaries, as well as lymph node metastasis. The postoperative course was uneventful, and the patient has been well without evidence of disease recurrence for 5 years following the operation. Preliminary reduction of adult colonic intussusception before surgical resection is therefore an option in cases of an early and correct diagnosis of intussusception.

11.
Oncology ; 82(3): 147-52, 2012.
Article in English | MEDLINE | ID: mdl-22433290

ABSTRACT

OBJECTIVES: Diamine oxidase (DAO) is an enzyme that catalyzes oxidation and is highly active in the mature upper villus cells of the intestinal mucosa. This study sought to evaluate plasma DAO activities during adjuvant chemotherapy in patients with gastric cancer. METHODS: We investigated 20 patients with gastric cancer who were treated with oral fluorouracil anti-cancer drugs as adjuvant chemotherapy. Plasma DAO activity was measured in all patients before chemotherapy and at 2, 4 and 6 weeks after the start of chemotherapy, and quality of life was evaluated simultaneously. RESULTS: The median DAO activity after 4 weeks of chemotherapy was significantly decreased compared to the pre-chemotherapy levels (6.6 vs. 7.5 U/l; p = 0.038). The changes in the rate of DAO activity at 2 and 6 weeks following the start of chemotherapy in patients with gastrointestinal tract toxicity were significantly lower than in those without toxicity (p =0.021 and 0.047, respectively). The patient cohort showed a slightly positive correlation between DAO activity and global health status and a negative correlation between DAO activity and appetite loss. CONCLUSIONS: Plasma DAO activities may be useful for monitoring and evaluating gastrointestinal tract toxicities induced by adjuvant chemotherapy with oral fluorouracil in patients with gastric cancer.


Subject(s)
Amine Oxidase (Copper-Containing)/metabolism , Antimetabolites, Antineoplastic/adverse effects , Fluorouracil/adverse effects , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/metabolism , Stomach Neoplasms/blood , Stomach Neoplasms/drug therapy , Administration, Oral , Adult , Aged , Antimetabolites, Antineoplastic/administration & dosage , Biomarkers, Tumor/blood , Female , Fluorouracil/administration & dosage , Gastrointestinal Tract/pathology , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Quality of Life , Stomach Neoplasms/enzymology
12.
Surg Today ; 42(7): 686-92, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22167483

ABSTRACT

We herein report a case of adult ileoileal intussusception induced by an ileal lipoma. A 68-year-old woman with a history of small intestinal tumors was admitted to our hospital with severe, colicky lower abdominal pain, similar to episodes experienced in the past. A barium meal enema at the initial admission demonstrated a small intestinal tumor in the ileum 30 cm proximal to the ileocecal valve. Abdominal ultrasound sonography and computed tomography showed a sausage-shaped mass presenting as a target sign in the right lower abdomen, suggestive of intussusception. There was also a round mass of fat attenuation representing a lipoma, which was considered the lead point of the intussusception. The patient underwent emergency surgery and partial resection of the ileum, including the ileal tumor, following reduction of the intussusception. The resected specimen contained a round tumor measuring 1.5 × 1.5 × 1.4 cm, which was diagnosed histopathologically as an intestinal lipoma. The patient made a satisfactory recovery and was discharged on postoperative day 10. The clinical characteristics of previously reported lipomas with intussusception are also discussed, including the relationships between the tumor size and symptoms or location.


Subject(s)
Ileal Diseases/etiology , Ileal Neoplasms/complications , Intussusception/etiology , Lipoma/complications , Aged , Female , Humans , Ileal Diseases/diagnosis , Ileal Diseases/surgery , Ileal Neoplasms/surgery , Intussusception/diagnosis , Intussusception/surgery , Lipoma/surgery
13.
Amino Acids ; 38(3): 901-7, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19399583

ABSTRACT

Glucose metabolism is adversely affected in patients following major surgery. Patients may develop hyperglycemia due to a combination of surgical stress and postoperative insulin resistance. A randomized trial was conducted to elucidate the effect of preoperative supplementation with carbohydrates and branched-chain amino acids on postoperative insulin resistance in patients undergoing hepatic resection. A total of 26 patients undergoing a hepatectomy for the treatment of a hepatic neoplasm were randomly assigned to receive a preoperative supplement of carbohydrate and branched-chain amino acid-enriched nutrient mixture or not. The postoperative blood glucose level and the total insulin requirement for normoglycemic control during the 16 h following hepatic resection were determined using the artificial pancreas STG-22. Postoperative insulin requirements for normoglycemic control in the group with preoperative nutritional support was significantly lower than that in the control group (P = 0.039). There was no incidence of hypoglycemia (<40 mg/dL) observed in patients, including those with diabetes mellitus, when the STG-22 was used to control blood glucose levels. STG-22 is a safe and reliable tool to control postoperative glucose metabolism and evaluate insulin resistance. The preoperative oral administration of carbohydrate and branched-chain amino acid-enriched nutrient is of clinical benefit and reduces postoperative insulin resistance in patients undergoing hepatic resection.


Subject(s)
Amino Acids, Branched-Chain/administration & dosage , Dietary Carbohydrates/administration & dosage , Dietary Supplements , Hepatectomy , Insulin Resistance , Pancreas, Artificial , Preoperative Care/methods , Aged , Amino Acids, Branched-Chain/adverse effects , Blood Glucose/analysis , Critical Care , Dietary Carbohydrates/adverse effects , Dietary Supplements/adverse effects , Female , Hepatectomy/mortality , Humans , Hyperglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Insulin/administration & dosage , Insulin/therapeutic use , Liver Neoplasms/surgery , Male , Middle Aged , Pancreas, Artificial/adverse effects , Postoperative Complications/prevention & control , Time Factors
14.
Med Mol Morphol ; 38(3): 181-8, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16170466

ABSTRACT

The effects of intraoperative radiotherapy on tumor cells were elucidated by immunohistochemical examination of changes in the level of proliferating cell nuclear antigen. In addition, the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling method was used to examine the level of apoptosis in mouse MM46 tumor cells after a single high dose of irradiation (30 Gy, 6 MeV). A significant decrease in the number of tumor cells compared to controls was observed on the 3rd, 7th, and 14th days following irradiation, but not on the 1st day. Consistent with these results, the proliferating cell nuclear antigen labeling index of irradiated cells decreased significantly on the 3rd, 7th, and 14th days following irradiation, but not on the 1st day. By comparison, the regrowth area on day 14 only showed no difference compared to the control group. The apoptotic index increased on the 7th and 14th day after irradiation, but at a lower rate than the observed decrease in the level of proliferating cell nuclear antigen. We speculate that the major mechanism of single high-dose radiation effect is inhibition of DNA synthesis.


Subject(s)
Apoptosis/radiation effects , Breast Neoplasms/metabolism , Breast Neoplasms/radiotherapy , Proliferating Cell Nuclear Antigen/metabolism , Animals , Breast Neoplasms/pathology , Cell Line, Tumor , Female , Immunohistochemistry , In Situ Nick-End Labeling , Mammary Glands, Animal/cytology , Mammary Glands, Animal/metabolism , Mammary Glands, Animal/radiation effects , Mice , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL